Identification of amino acid residues in HIV-1 Vif critical for binding and exclusion of APOBEC3G/F
- PMID: 18603011
- DOI: 10.1016/j.micinf.2008.06.003
Identification of amino acid residues in HIV-1 Vif critical for binding and exclusion of APOBEC3G/F
Abstract
To define a region(s) in human immunodeficiency virus type 1 (HIV-1) Vif that involves binding to its target APOBEC3G (A3G), we have generated a series of site-specific proviral vif mutants. Of 30 mutants examined, 15 did not grow at all or grew more poorly than wild-type virus in non-permissive cells. Eight clones with N-terminal mutations located outside of the HCCH motif and BC-box, which are known to be directly crucial for the degradation of A3G, were chosen from these growth-defective mutants and mainly analyzed in detail for functional activity of their mutant Vif proteins. By single-cycle replication and immunoprecipitation/immunoblotting analyses, mutants designated W21A, S32A, W38A, Y40A, and H43A were demonstrated to hardly or poorly bind to and neutralize A3G. Upon transfection, these mutants produced progeny virions containing much more A3G than wild-type clone. Interestingly, while mutants designated E76A and W79A acted normally to inactivate A3G, they were found to exhibit a Vif-defective phenotype against A3F. Another unique mutant designated Y69A incompetent against both of A3G/F was also identified. Our results here have indicated that at least two distinct regions in the N-terminal half of HIV-1 Vif are critical for binding and exclusion of A3G/F.
Similar articles
-
APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.J Virol. 2016 Apr 14;90(9):4681-4695. doi: 10.1128/JVI.03275-15. Print 2016 May. J Virol. 2016. PMID: 26912618 Free PMC article.
-
Status of APOBEC3G/F in cells and progeny virions modulated by Vif determines HIV-1 infectivity.Microbes Infect. 2010 Feb;12(2):166-71. doi: 10.1016/j.micinf.2009.11.007. Epub 2009 Nov 26. Microbes Infect. 2010. PMID: 19944180
-
Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.J Mol Biol. 2008 Sep 12;381(4):1000-11. doi: 10.1016/j.jmb.2008.06.061. Epub 2008 Jun 28. J Mol Biol. 2008. PMID: 18619467
-
Various strategies for developing APOBEC3G protectors to circumvent human immunodeficiency virus type 1.Eur J Med Chem. 2023 Mar 15;250:115188. doi: 10.1016/j.ejmech.2023.115188. Epub 2023 Feb 6. Eur J Med Chem. 2023. PMID: 36773550 Review.
-
[Progress in the study of HIV-1 Vif and related inhibitors].Yao Xue Xue Bao. 2010 Jun;45(6):684-93. Yao Xue Xue Bao. 2010. PMID: 20939174 Review. Chinese.
Cited by
-
Multifaceted HIV-1 Vif interactions with human E3 ubiquitin ligase and APOBEC3s.FEBS J. 2021 Jun;288(11):3407-3417. doi: 10.1111/febs.15550. Epub 2020 Sep 21. FEBS J. 2021. PMID: 32893454 Free PMC article.
-
Differential anti-APOBEC3G activity of HIV-1 Vif proteins derived from different subtypes.J Biol Chem. 2010 Nov 12;285(46):35350-8. doi: 10.1074/jbc.M110.173286. Epub 2010 Sep 10. J Biol Chem. 2010. PMID: 20833716 Free PMC article.
-
APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.J Virol. 2016 Apr 14;90(9):4681-4695. doi: 10.1128/JVI.03275-15. Print 2016 May. J Virol. 2016. PMID: 26912618 Free PMC article.
-
Structural perspectives on HIV-1 Vif and APOBEC3 restriction factor interactions.Protein Sci. 2020 Feb;29(2):391-406. doi: 10.1002/pro.3729. Epub 2019 Nov 29. Protein Sci. 2020. PMID: 31518043 Free PMC article. Review.
-
HIV-1 VIF and human APOBEC3G interaction directly observed through molecular specific labeling using a new dual promotor vector.J Magn Reson. 2022 Jun;339:107230. doi: 10.1016/j.jmr.2022.107230. Epub 2022 Apr 26. J Magn Reson. 2022. PMID: 35550909 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources